id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-253840-xudra8tp	Gillette, Michael	Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare	2020-04-21		.txt	text/plain	3316	155	41	Over the preceding 12-24 months, healthcare providers have encountered an alarming number of recalls related to cardiovascular medications, particularly with angiotensin receptor blockers (ARBs). ARBs, such as valsartan and losartan, represent a class of medications that in randomized controlled clinical trials (RCTs) have been shown to reduce blood pressure (BP) in hypertensive patients and impart cardiovascular benefits in diabetic nephropathy, systolic heart failure, left ventricular dysfunction, and following stroke [1] [2] [3] [4] [5] [6] [7] [8] 10] . This is particularly important given the recent outbreak of the coronavirus disease 2019 (COVID19) and speculation that ACE-Is or ARBs could increase the risk of infection through upregulation of angiotensin converting enzyme-2 receptors (ACE2) thereby leading to inappropriate discontinuation by patients or providers [16] . Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial	./cache/cord-253840-xudra8tp.txt	./txt/cord-253840-xudra8tp.txt